Document Detail


Percent free prostate-specific antigen does not improve the effectiveness of prostate cancer detection in Chinese men with a prostate-specific antigen of 2.5-20.0 ng/ml: a multicenter study.
MedLine Citation:
PMID:  24659324     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The prostate-specific antigen (PSA) "gray zone" in Chinese men is likely higher than the traditional value (2.5-10.0 ng/ml) since the incidence of prostate cancer in Chinese men is relative low. The utility of percent free PSA in predicting prostate cancer is based on Western populations and may introduce sizable bias when applied to a Chinese cohort. We assessed the efficacy of percent free PSA in predicting prostate cancer in Chinese men with a PSA of 2.5-10.0 and 10.1-20.0 ng/ml. A total of 558 men with a PSA of 2.5-20.0 ng/ml who had undergone prostatic biopsy to detect prostate cancer from two Chinese centers were included. The rates of prostate cancer in different percent free PSA ranges were evaluated. Receiver operating characteristic curve (ROC) was used to evaluate and compare the efficiency of PSA and percent free PSA in the diagnosis of prostate cancer. The areas under ROC (AUCs) for percent free PSA for predicting prostate cancer were not higher than those for PSA, although prostate cancer detection rates increased with decreased percent free PSA in men with a PSA of 2.5-10.0, 10.1-20.0, and 2.5-20.0 ng/ml. Similarly, for men aged <70 and ≥70 years and with prostate volume <40 and ≥40 ml, AUCs showed percent free PSA was not better than PSA in predicting prostate cancer. By analyzing multicenter data, we first found that percent free PSA does not improve detection of prostate cancer in Chinese men with a PSA of 2.5-10.0 or 10.1-20.0 ng/ml.
Authors:
Maping Huang; Yurong Lin; Abai Xu; Matthew Uhlman; Xiangrong Deng; Xuanting Lin; Sifeng Wu; Pengfei Diao; Keji Xie; Ping Tang
Related Documents :
11494314 - The role of chemoattraction in cancer metastases.
15541184 - Large bilateral adrenal metastases in non-small cell lung cancer.
23764994 - Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for bi-ra...
9725004 - Association of breast cancer with meningioma.
18812704 - Breast necrosis following left internal mammary artery harvest: a case series and a com...
6772294 - Current status of clinical particle radiotherapy at lawrence berkeley laboratory.
Publication Detail:
Type:  Journal Article     Date:  2014-03-23
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  31     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-03-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  925     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Contribution of retinal ganglion cells to the mouse electroretinogram.
Next Document:  Morphological changes produced by acid dissolution in Er:YAG laser irradiated dental enamel.